课题基金 / 基金详情

Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in cancer

Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in cancer
剖析和靶向 EZH2 在癌症中的典型和非典型致癌功能
批准号:
10544005
负责人:
Jian Jin
金额:
$47.93万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-01-01 至 2023-07-31

项目摘要

项目成果

Jian Jin的其他基金

相似基金

相关文献

中文摘要
翻译
项目概要/摘要 携带MLL1重排的白血病患者通常表现出非常差的预后,需要新的治疗 治疗策略。多项独立研究已鉴定出 EZH2(一种组蛋白甲基转移酶)和 Polycomb 抑制复合物 2 (PRC2) 的催化亚基,作为 MLL1 重排中有吸引力的药物靶点 白血病。然而,目前EZH2的催化抑制剂的抗肿瘤作用有限。我们的初步 研究表明,EZH2 还结合 c-MYC,并在癌基因(例如 MLL1 重排白血病中的 Cyclin E1),这与众所周知的 PRC2:EZH2 驱动的规范不同 与基因抑制相关的功能。为了通过以下方式针对典型和非典型致癌作用 EZH2,我们使用蛋白水解靶向嵌合体 (PROTAC) 技术来生成新型 EZH2 小分子 分子降解剂,包括 MS177。 Our extensive preliminary studies have demonstrated that MS177 有效降解 PRC2:EZH2 和 EZH2 的非 PRC2 伴侣(例如 c-MYC,它将 EZH2 结合到 激活致癌基因),从而抑制 EZH2 的典型和非典型致癌活性 肿瘤。重要的是,我们的初步结果还表明 MS177 优于所有酶抑制剂 EZH2 治疗 MLL1 重排白血病。因此,我们假设:(1)EZH2 具有较少研究的、非 canonical oncogenic function, which acts in parallel with the PRC2:EZH2-dependent one to produce more MLL1 重排白血病中出现侵袭性肿瘤表型; (2) 针对规范和非规范 PROTACs 对 EZH2 的典型活性代表了一种新颖且优于抑制 EZH2 的治疗策略 EZH2 单独的酶活性。 Dissection of the mechanisms underlying EZH2-mediated oncogenesis and development of an optimal EZH2 PROTAC as a drug candidate will have significant impact on improving MLL1重排白血病患者的治疗。为了实现这一目标,我们将进一步描述这种新的 EZH2 在 MLL1 重排白血病中的非典型致癌作用(目标 1a)并定义 EZH2 的作用 PROTAC 抑制 EZH2 的典型和非典型致癌活性(目标 1b)。我们会 还通过采用多个独立的方法确定 EZH2 PROTAC 的体外和体内治疗效果 MLL1 重排白血病模型,包括人/鼠癌细胞和患者来源的异种移植物 (PDX) (目标 2)。最后,我们将优化 EZH2 PROTAC 线索,使其成为候选药物(目标 3)。完成 拟议的研究不仅将为 MLL1 重排白血病提供新的机制理解 开发,但也将验证创新的治疗策略并提供有前途的治疗候选药物 用于治疗受影响的癌症患者。
英文摘要
PROJECT SUMMARY/ABSTRACT Leukemia patients bearing MLL1 rearrangement generally display very poor prognosis, demanding new treatment strategies. Multiple independent studies have identified EZH2, a histone methyltransferase and catalytic subunit of Polycomb Repressive Complex 2 (PRC2), as an attractive drug target in MLL1-rearranged leukemias. However, the current catalytic inhibitors of EZH2 have limited anti-tumor effect. Our preliminary studies show that EZH2 also binds c-MYC and has a non-canonical function in activation of oncogenes (such as Cyclin E1) in MLL1-rearranged leukemias, which differs from the well-known PRC2:EZH2-driven canonical function related to gene repression. In order to target both canonical and non-canonical oncogenic actions by EZH2, we used the Proteolysis Targeting Chimera (PROTAC) technology to generate novel EZH2 small- molecule degraders including MS177. Our extensive preliminary studies have demonstrated that MS177 effectively degrades both PRC2:EZH2 and non-PRC2 partners of EZH2 (e.g., c-MYC, which binds EZH2 to activate oncogenes), thus suppressing both canonical and non-canonical oncogenic activities of EZH2 in tumor. Importantly, our preliminary results also show that MS177 is superior to all of enzymatic inhibitors of EZH2 in treating MLL1-rearranged leukemias. Thus, we hypothesize that: (1) EZH2 has a less-studied, non- canonical oncogenic function, which acts in parallel with the PRC2:EZH2-dependent one to produce more aggressive tumor phenotypes seen in MLL1-rearranged leukemias; and (2) targeting both canonical and non- canonical activities of EZH2 by PROTACs represents a novel and superior therapeutic strategy to inhibition of EZH2’s enzymatic activity alone. Dissection of the mechanisms underlying EZH2-mediated oncogenesis and development of an optimal EZH2 PROTAC as a drug candidate will have significant impact on improving treatments for MLL1-rearranged leukemia patients. Towards this goal, we will further characterize such a new non-canonical oncogenic role of EZH2 in MLL1-rearranged leukemias (Aim 1a) and define effects of EZH2 PROTACs on suppressing both canonical and non-canonical oncogenic activities of EZH2 (Aim 1b). We will also determine in vitro and vivo therapeutic effects of EZH2 PROTACs by employing multiple independent MLL1-rearranged leukemia models including human/murine cancer cells and patient-derived xenografts (PDX) (Aim 2). Lastly, we will optimize our EZH2 PROTAC leads into a drug candidate (Aim 3). Completion of the proposed research will not only provide novel mechanistic understanding of how MLL1-rearranged leukemias develop, but will also validate an innovative therapeutic strategy and deliver a promising therapeutic candidate for the treatment of affected cancer patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Inhibitors of Lysine Methyltransferases G9a and GLP for the Treatment of Alzheimer's Disease
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in cancer
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in caner
  • 批准号:
    10908135
  • 项目类别:
  • 资助金额:
    $23.07万
  • 财政年份:
    2022
  • 负责人:
    Jian Jin
  • 依托单位:
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias
海外基金